- Home
- CROX vs CYTK Comparison
CROX vs CYTK Comparison
Compare CROX & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CROX
- CYTK
- Stock Information
- Founded
- CROX 1999
- CYTK 1997
- Country
- CROX United States
- CYTK United States
- Employees
- CROX 7910
- CYTK N/A
- Industry
- CROX Shoe Manufacturing
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- CROX Consumer Discretionary
- CYTK Health Care
- Exchange
- CROX Nasdaq
- CYTK Nasdaq
- Market Cap
- CROX 3.9B
- CYTK 4.6B
- IPO Year
- CROX 2006
- CYTK 2004
- Fundamental
- Price
- CROX $74.21
- CYTK $65.80
- Analyst Decision
- CROX Buy
- CYTK Strong Buy
- Analyst Count
- CROX 12
- CYTK 15
- Target Price
- CROX $100.92
- CYTK $77.87
- AVG Volume (30 Days)
- CROX 1.9M
- CYTK 1.8M
- Earning Date
- CROX 10-30-2025
- CYTK 11-05-2025
- Dividend Yield
- CROX N/A
- CYTK N/A
- EPS Growth
- CROX N/A
- CYTK N/A
- EPS
- CROX 3.26
- CYTK N/A
- Revenue
- CROX $4,072,780,000.00
- CYTK $87,211,000.00
- Revenue This Year
- CROX N/A
- CYTK $363.61
- Revenue Next Year
- CROX N/A
- CYTK $64.33
- P/E Ratio
- CROX $22.74
- CYTK N/A
- Revenue Growth
- CROX 0.01
- CYTK 2609.26
- 52 Week Low
- CROX $73.52
- CYTK $29.31
- 52 Week High
- CROX $122.84
- CYTK $66.98
- Technical
- Relative Strength Index (RSI)
- CROX 35.23
- CYTK 65.35
- Support Level
- CROX $73.52
- CYTK $58.05
- Resistance Level
- CROX $80.11
- CYTK $66.98
- Average True Range (ATR)
- CROX 3.34
- CYTK 2.64
- MACD
- CROX -0.87
- CYTK 0.27
- Stochastic Oscillator
- CROX 5.13
- CYTK 85.11
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.